McKesson to acquire Precision Medicine Group for $2.25bn
US-based healthcare services provider McKesson has agreed to buy Precision Medicine Group for $2.25bn. McKesson believes that the deal will…
25 Aug 2026
J&J’s Imaavy secures expanded US approval in rare blood disorder
The US Food and Drug Administration (FDA) has expanded the label indication of Johnson & Johnson’s (J&J) Imaavy (nipocalimab-aahu) to treat a rare blood disorder, boosting the drug’s blockbuster credentials.…
25 Aug 2026
GSK snags Japanese approval for first hepatitis B functional cure, Hibsago
GSK has netted the first approval globally for its chronic hepatitis B therapy, bepirovirsen, from Japan’s Ministry of Health, Labour and Welfare (MHLW) – marking the first entry of a…
25 Aug 2026
Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin. This regulatory status is designed…
25 Aug 2026
FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial
REGENXBIO has reported that the US Food and Drug Administration (FDA) has placed a clinical hold on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), developed for the treatment of mucopolysaccharidosis…
25 Aug 2026
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
Takeda has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Orzeyful (oveporexton) to treat narcolepsy type 1 in adults. This decision makes Orzeyful the only treatment…
24 Aug 2026
Roche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate
Roche has conducted its joint-largest deal of the year so far, licensing a clinical-stage UCN2 (urocortin-2) analog being developed for weight loss by South Korea-based Hanmi Pharm. The Swiss big…